to-BBB Further Strengthens Supervisory Board with Dr. Peter Høngaard Andersen

12-Sep-2013 - Netherlands

to-BBB announced the addition of Dr. Peter Høngaard Andersen to its Supervisory Board. Dr. Andersen brings many years of pharma drug development experience to the Board. His experience and strategic guidance will be instrumental to further build to-BBB as a leading company in brain drug development.

Dr. Peter Høngaard Andersen is currently the Sr. VP Global Public Affairs and Corporate Patents & Trademarks at Lundbeck, the Danish global pharma company focused on brain diseases. He previously held multiple senior R&D positions for Lundbeck and Novo Nordisk. Dr. Andersen holds degrees in chemistry, biochemistry and medicine from University of Copenhagen. He currently holds Board seats at Epitherapeutics and at Prexton Therapeutics, as well as board positions for the European pharmaceutical industry (EFPIA and IMI).

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances